Attillaps Pharmaceuticals · Dermatology & Ophthalmology
Advancing Therapeutic Innovation
in Demodex-Driven Disease
Attillaps Holdings is a pharmaceutical platform company developing targeted therapies for inflammatory conditions associated with Demodex mites. Through a proprietary patent portfolio and strategic partnerships, including GLK-321 in collaboration with Glaukos Corporation, we are advancing novel treatments with significant clinical and commercial potential.
We are pioneering therapies targeting Demodex-associated inflammatory diseases across ophthalmology and dermatology — combining mechanistic insight with translational development to unlock high-value clinical opportunities.
Our Company
Building the Science to Defeat Demodex
Attillaps Holdings is a pharmaceutical holding company with a mission to unlock the therapeutic potential of Demodex mite biology across inflammatory and dermatological diseases. We combine a robust patent portfolio with rigorous translational science to develop and partner best-in-class treatments that address unmet medical needs.
From Demodex blepharitis to cutaneous autoimmune diseases and common dermatological conditions — rosacea, acne, and beyond — where Demodex is implicated in driving inflammation, Attillaps is building the scientific foundation to address the root cause.
Our Science →
Our Approach
A platform built on proprietary IP,
out-licensed to world-class partners.
Attillaps Holdings leverages a proprietary patent portfolio to develop treatments for inflammatory diseases driven by Demodex mites — out-licensing to world-class pharmaceutical partners who bring these therapies to patients at scale.
A Ubiquitous Pathogen.
A Largely Untreated Disease Spectrum.
Demodex mites are found on virtually every human adult. For most people, the immune system silently keeps them in check. But for millions of patients worldwide, a breakdown in immune regulation allows these mites to drive chronic, recurrent inflammatory disease affecting the eyes, skin, and beyond.
Attillaps Holdings has built a proprietary drug platform designed to address the antigen driving the underlying immune dysfunction — not just the symptoms. Our approach creates a new category of treatment across multiple unmet clinical indications.
Strategic Milestone
Platform validation through
world-class partnership.
GLK-321 Licensed to Glaukos Corporation for Demodex Blepharitis
Our lead compound, GLK-321, is now in development with Glaukos Corporation — a global leader in ophthalmology. This out-license validates the Attillaps platform and marks a significant milestone in our mission to create novel new therapeutics in cutaneous inflammatory diseases.
Contact Us →Learn More About the Attillaps Platform
The first integrated IP estate targeting the root cause of Demodex-driven inflammatory disease — across dermatology, ophthalmology, and rheumatology.